Safety and Efficacy Study of AVB-S6-500 in Patients With Advanced Clear Cell Renal Cell Carcinoma
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1b/2 study of AVB-S6-500 designed to evaluate the safety and efficacy of
AVB-S6-500 in combination with cabozantinib in subjects with advanced clear cell renal cell
carcinoma (ccRCC) that have progressed on or after at least one prior line of treatment. The
phase 1b portion of the study is open label and patients will receive AVB-S6-500+Cabozantinib
in 3+3 dose escalation. The Phase 2 portion of the study is randomized, 2-arm, open-label
study to compare efficacy and tolerability of AVB-S6-500+cabozantinib versus cabozantinib
alone